A ruptured gastrointestinal stromal tumour of the small intestine: a case report

Abstract

The management of Gastrointestinal Stromal Tumours (GISTs) has evolved rapidly since imatinib was introduced. Surgery remains the first-line treatment for localised, primary GIST, but the risk for local or metastatic relapse of disease is very high. Prognostic assessment is a critical part of developing a treatment strategy. Perforation or rupture of a GIST to the abdominal cavity has a very high risk for recurrence. We described the case of a 51-year-old man with a haemoperitoneum caused by a ruptured primary GIST of the small intestine. After complete surgical resection, imatinib given for two years as adjuvant therapy achieved no disease progression after prolonged follow-up.

Keywords

• Ruptured gastrointestinal stromal tumour (GIST)
• Small intestine
• Adjuvant imatinib